AU2015204770B2 - Treatment of human immunodeficiency virus/acquired immunodeficiency syndrome - Google Patents

Treatment of human immunodeficiency virus/acquired immunodeficiency syndrome Download PDF

Info

Publication number
AU2015204770B2
AU2015204770B2 AU2015204770A AU2015204770A AU2015204770B2 AU 2015204770 B2 AU2015204770 B2 AU 2015204770B2 AU 2015204770 A AU2015204770 A AU 2015204770A AU 2015204770 A AU2015204770 A AU 2015204770A AU 2015204770 B2 AU2015204770 B2 AU 2015204770B2
Authority
AU
Australia
Prior art keywords
composition
hiv
patient
cells
viral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2015204770A
Other languages
English (en)
Other versions
AU2015204770A1 (en
Inventor
Michael Har-Noy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunovative Therapies Ltd
Original Assignee
Immunovative Therapies Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunovative Therapies Ltd filed Critical Immunovative Therapies Ltd
Publication of AU2015204770A1 publication Critical patent/AU2015204770A1/en
Application granted granted Critical
Publication of AU2015204770B2 publication Critical patent/AU2015204770B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2015204770A 2014-01-08 2015-01-08 Treatment of human immunodeficiency virus/acquired immunodeficiency syndrome Ceased AU2015204770B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461924936P 2014-01-08 2014-01-08
US61/924,936 2014-01-08
PCT/US2015/010658 WO2015105999A1 (en) 2014-01-08 2015-01-08 Treatment of human immunodeficiency virus/acquired immunodeficiency syndrome

Publications (2)

Publication Number Publication Date
AU2015204770A1 AU2015204770A1 (en) 2016-08-18
AU2015204770B2 true AU2015204770B2 (en) 2020-07-02

Family

ID=53494410

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015204770A Ceased AU2015204770B2 (en) 2014-01-08 2015-01-08 Treatment of human immunodeficiency virus/acquired immunodeficiency syndrome

Country Status (12)

Country Link
US (3) US10272143B2 (enExample)
EP (1) EP3091990B1 (enExample)
JP (1) JP6557240B2 (enExample)
KR (1) KR102503400B1 (enExample)
CN (1) CN105899219B (enExample)
AU (1) AU2015204770B2 (enExample)
BR (1) BR112016015736B1 (enExample)
CA (1) CA2936086C (enExample)
IL (1) IL246643B (enExample)
PH (1) PH12016501359A1 (enExample)
SG (2) SG10201908048QA (enExample)
WO (1) WO2015105999A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150305983A1 (en) * 2009-11-20 2015-10-29 The University Of Versailles Saint-Quentin-En- Yvelines Quadruple therapy useful for treating persons afflicted with the human immunodeficiency virus (hiv)
US20190069528A1 (en) * 2016-03-21 2019-03-07 The George Washington University Engineered human hookworms as a novel biodelivery system for vaccines and biologicals
CN111886249A (zh) * 2017-09-18 2020-11-03 西托戴恩股份有限公司 用于鉴定和治疗适合长期抗-ccr5剂治疗的hiv-1感染患者亚群的筛选方法
USD1001795S1 (en) 2019-10-01 2023-10-17 Microsoft Corporation Computing device

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100086561A1 (en) * 2008-10-01 2010-04-08 Immunovative Therapies Ltd. Th1 vaccination priming for active immunotherapy

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020022034A1 (en) * 1997-09-15 2002-02-21 Julianna Lisziewicz Therapeutic DNA vaccination
WO2000066141A2 (en) 1999-05-04 2000-11-09 Schering Corporation Pegylated interferon alfa-ccr5 antagonist combination hiv therapy
US6579521B2 (en) 2000-10-20 2003-06-17 Chiron Corporation Methods of therapy for HIV infection
US7402431B2 (en) 2004-03-01 2008-07-22 Immunovative Therapies, Ltd. T-cell therapy formulation
US20110142887A1 (en) * 2009-12-15 2011-06-16 Immunovative Therapies Ltd. Methods and compositions for liquidation of tumors
US7435592B2 (en) 2003-05-13 2008-10-14 Immunovative Therapies, Ltd. Compositions for allogeneic cell therapy
KR20070019635A (ko) * 2003-08-28 2007-02-15 더 임뮨 리스판스 코포레이션 면역원성 ｈｉｖ 조성물 및 이와 관련된 방법
OA13246A (en) 2003-08-28 2007-01-31 Immune Response Corp Inc Immunogenic HIV Compositions and related methods.
JP2007525225A (ja) * 2004-02-26 2007-09-06 イミュノバティブ セラピーズ， リミテッド 細胞治療のためのｔ細胞を調製するための方法
EP1749090B1 (en) 2004-03-01 2017-05-17 Immunovative Therapies, Ltd. Cell therapy formulation method and composition
US8043619B2 (en) * 2004-10-08 2011-10-25 Yaron Ilan Methods and uses of leptin in immune modulation
US20120128656A1 (en) 2008-05-02 2012-05-24 Immunovative Therapies, Ltd. Vaccine compositions and methods
WO2010051521A1 (en) 2008-10-31 2010-05-06 Lentigen Corporation Cell therapy product for the treatment of hiv infection
WO2011077100A1 (en) * 2009-12-24 2011-06-30 Cipla Limited Antiretroviral composition
MX2012011189A (es) 2010-03-26 2013-02-07 Glaxosmithkline Biolog Sa Vacuna contra el virus e inmunodeficiencia humana.
AU2011240752B2 (en) * 2010-04-13 2016-07-28 Immunovative Therapies, Ltd. Methods and compositions for inhibition of Treg cells
WO2011130247A2 (en) 2010-04-14 2011-10-20 The Penn State Research Foundation Strategies for the transgenic manipulation of filamentous fungi

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100086561A1 (en) * 2008-10-01 2010-04-08 Immunovative Therapies Ltd. Th1 vaccination priming for active immunotherapy

Also Published As

Publication number Publication date
US10729754B2 (en) 2020-08-04
EP3091990A4 (en) 2017-10-04
IL246643A0 (en) 2016-08-31
AU2015204770A1 (en) 2016-08-18
JP2017502058A (ja) 2017-01-19
WO2015105999A1 (en) 2015-07-16
EP3091990A1 (en) 2016-11-16
BR112016015736A2 (enExample) 2017-08-08
US20180200348A1 (en) 2018-07-19
PH12016501359A1 (en) 2016-08-22
EP3091990B1 (en) 2021-05-12
CA2936086A1 (en) 2015-07-16
CN105899219A (zh) 2016-08-24
SG10201908048QA (en) 2019-10-30
US20150190488A1 (en) 2015-07-09
IL246643B (en) 2020-02-27
US20200368334A1 (en) 2020-11-26
US10272143B2 (en) 2019-04-30
KR20160124096A (ko) 2016-10-26
CA2936086C (en) 2024-02-27
CN105899219B (zh) 2021-08-13
SG11201605440TA (en) 2016-08-30
BR112016015736B1 (pt) 2022-01-04
KR102503400B1 (ko) 2023-02-23
JP6557240B2 (ja) 2019-08-07

Similar Documents

Publication Publication Date Title
Hel et al. HIV infection: first battle decides the war
US20200368334A1 (en) Treatment of human immunodeficiency virus/acquired immunodeficiency syndrome
Pantaleo et al. Therapeutic vaccines and immunological intervention in HIV infection: a paradigm change
Pantaleo et al. Vaccine and immunotherapeutic interventions
Van Gulck et al. Role of dendritic cells in HIV-immunotherapy
WO2018208606A1 (en) Protective chimeric antigen receptor stem cell gene therapy for viral infection
TWI714529B (zh) 人類免疫缺乏病毒/後天性免疫缺乏症候群之治療
HK1227297B (en) Treatment of human immunodeficiency virus/acquired immunodeficiency syndrome
HK1227297A1 (en) Treatment of human immunodeficiency virus/acquired immunodeficiency syndrome
Calarota et al. Cellular HIV-1 immune responses in natural infection and after genetic immunization
Huber Human circulating T follicular helper cells during viral infection and autoimmunity
Giese Vaccinating against Cancer–How to Force the Quatrature of the Circle
Kim et al. Immunotherapeutic restoration in HIV-infected individuals
Yager Natural and therapy-induced immune control of HIV-1
Lori Virostatics: A new frontier in the treatment of HIV/AIDS
Chibbar et al. GP120-SPECIFIC EXOSOME-TARGETED T CELL-BASED VACCINE CAPABLE OF STIMULATING DC-AND CD4+ T-INDEPENDENT CTL RESPONSES
Lederman Immune success and immune failure in HIV infection: implications for therapeutic intervention
Miller HYDROXYUREA: EIGHT YEARS'EXPERIENCE
Bentwitch MICRO RNA AND HIV
Clotet Treatment Interruptions Guided by CD4 Counts and Viral Load
Maserati Therapeutic Vaccination With A Gp120-Depleted Whole Killed Virus Vaccine Candidate (Remune) in Antiretroviral-Naive Hiv-Infected Patients
Silvestri Naturally Occurring Immunomodulation: Siv Infection in Sooty Mangabeys
Wainberg Does Impaired HIV Viral Fitness Result in Enhanced Durability of the Anti-HIV Immune Response?
Autran Therapeutic Immunization Against HIV
Kinloch The Quest Study, From a Clinician With Immunological Inclination

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired